Stephens Consulting’s Avanos Medical AVNS Stock Holding History

Stephens Consulting’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-25	Closed	-$359	–	1276
2025 Q1	$359	Buy	+25	New	+$390	﹤0.01%	1273

Other funds holding AVNS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Stephens Consulting's AVNS Position: Q2 2025 in Review

Stephens Consulting sold out of Avanos Medical (AVNS) in Q2 2025, closing a stake of 25 shares — an estimated $359 sold.

Stephens Consulting first reported a position in AVNS in Q1 2025 and held it in 1 quarter. The position peaked at $359 in Q1 2025. 286 funds tracked by Wall St. Rank hold AVNS as of Q2 2025.

Stephens Consulting reported no remaining Avanos Medical position as of Q2 2025 after selling out during the quarter.
Stephens Consulting sold 25 Avanos Medical shares in Q2 2025, an estimated $359.
Stephens Consulting first reported a position in Avanos Medical in Q1 2025 and held it in 1 quarter.
Stephens Consulting's Avanos Medical position peaked at $359 in Q1 2025.
286 funds tracked by Wall St. Rank held Avanos Medical as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.